Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
PURE Bioscience Boosts Balance Sheet by New Financing
Grang Zeng, CFA
Early today, PURE Bioscience, Inc. ( PURE ) announced the pricing of an underwritten public offering of 3,784,000 shares of its common stock, offered at a price to the public of $1.10 per share.
The gross proceeds to PURE from this offering are expected to be $4,162,400, before deducting the underwriting discount and other estimated offering expenses payable by PURE. PURE has granted the underwriters a 45-day option to purchase at the public offering price up to an aggregate of 567,600 additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about September 17, 2012, subject to customary closing conditions.
The offering is being made pursuant to a shelf registration statement that PURE filed with the SEC and is effective.
While some investors view this offering negative, but we see this financing positive in the long run.
This offering will boost the Company’s balance sheet immediately. As we pointed out before, cash burn is our chief concern. As of April 30, 2012, the Company had cash and cash equivalents of approximately $0.3 million. With proceeds from this offering, the Company should have cash on hand of approximately $4 million, which will last through the end of 2012.
Recently, PURE reported strong financial results for its third fiscal quarter ended April 30, 2012.
Revenue for the quarter was $207,000, compared with revenue of $128,000 for the same quarter of the prior year, an increase of 61.2%.
Gross margin as a percentage of net product sales was 82% and 71% for the three months ended April 30, 2012 and 2011, respectively. Going forward, we believe PURE can maintain a gross margin of 75-80% depending on product mix it markets. This is pretty impressive.
The net loss for the quarter was $1.8 million, or $0.04 per share, compared with a net loss of $1.8 million, or $0.05 per share, in the third quarter last year.
Revenue for the nine months ended April 30, 2012 was $685,000, compared with revenue of $220,000 for the nine months ended April 30, 2011. The net loss for the nine months ended April 30, 2012 was $6.4 million, or $0.15 per share, compared with a net loss of $6.3 million, or $0.17 per share, for the nine months ended April 30, 2011.
With the balance sheet boosted, PURE is in a better position to execute its long term growth strategy.
Please visit scr.zacks.com to access a free copy of the full research report.
Read the full reports :
on PURE